Antibody-mediated Rejection Market is segmented By Treatment (Plasma Exchange, IVIG, Complement Inhibitors, Proteasome Inhibitors), By Drugs in Development (Clazakizumab, Imlifidase), By Therapeutic Approach (Monoclonal Antibodies, Complement Inhibitors), By Patient Type (Pre-sensitized Transplant Recipients, Acute AMR Patients), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD million) for the above-mentioned.